FDA Offers Sponsors a New Electronic Device-Application Template
Published Date: 10/28/2026
Notice
Summary
The FDA just dropped a draft guide to help medical device sponsors submit their Investigational Device Exemption (IDE) applications electronically. This new template aims to make submissions easier, more consistent, and speed up the review process. If you’re involved in medical device development, check it out and send your feedback by December 28, 2026—no cost, just your input!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Draft electronic IDE submission template
If you sponsor medical devices and submit Investigational Device Exemption (IDE) applications to FDA centers CDRH or CBER, FDA published a draft guidance titled "Electronic Submission Template for Investigational Device Exemption (IDE) Applications" to introduce publicly available resources to support electronic submissions of original IDEs, supplements, and amendments. The draft guidance is intended to improve submission consistency and enhance efficiency in the review process; FDA is accepting comments on the draft through December 28, 2026.
Path to electronic-only IDE submission rules
When finalized, the guidance will provide standards, a timetable, and criteria for waivers and exemptions under section 745A(b) of the Federal Food, Drug, and Cosmetic Act, which addresses submissions solely in electronic format. The draft states that to the extent it provides such mandatory standards or criteria, those provisions would implement the statutory requirements and could be legally enforceable.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-21952, Science Advisory Board
NOAA’s Science Advisory Board is holding a public meeting on November 17-18, 2026, in Washington, DC, to discuss important science and environmental topics. This meeting affects scientists, policymakers, and anyone interested in how NOAA shapes research and resource management. It’s a chance to hear updates, share your thoughts during the public comment time, and stay in the loop on NOAA’s future plans—all free and open to the public!
Next: 2026-21954, Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help companies get approval for personalized human genome editing products all in one go. This means easier ways to add new gene edits after approval, saving time and money for innovators and patients alike. If you’re in the gene-editing game, jump in with your feedback by November 27, 2026, to shape the final rules!